Pilot trial on the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration: a single-arm, open-label study
Abstract Objective This study aimed to explore the efficacy and safety of pantethine in children with pantothenate kinase-associated neurodegeneration (PKAN). Methods A single-arm, open-label study was conducted. All subjects received pantethine during the 24-week period of treatment. The primary en...
Main Authors: | Xuting Chang, Jie Zhang, Yuwu Jiang, Bufan Yao, Jingmin Wang, Ye Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13023-020-01530-5 |
Similar Items
-
Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels
by: Mónica Álvarez-Córdoba, et al.
Published: (2022-08-01) -
Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration
by: Mónica Álvarez-Córdoba, et al.
Published: (2023-09-01) -
Pantethine as source for pantothenic acid added as a nutritional substance in food supplements ‐ Scientific Opinion of the Panel on Food Additives and Nutrient Sources added to Food (ANS)
by: European Food Safety Authority (EFSA)
Published: (2008-11-01) -
Novel Compound Heterozygous Mutations in the Pantothenate Kinase 2 Gene in a Korean Patient with Atypical Pantothenate Kinase Associated Neurodegeneration
by: Sung-Hyouk Kim, et al.
Published: (2009-05-01) -
Precision medicine in pantothenate kinase-associated neurodegeneration
by: Mónica Alvarez-Cordoba, et al.
Published: (2019-01-01)